OTC: SPHRF - Starpharma Holdings Limited

Yield per half year: -12.5%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Starpharma Holdings Limited


About Starpharma Holdings Limited

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray.

more details
In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://starpharma.com
Цена ао 0.07
Change price per day: 0% (0.07)
Change price per week: 0% (0.07)
Change price per month: -22.22% (0.09)
Change price per 3 month: 0% (0.07)
Change price per half year: -12.5% (0.08)
Change price per year: -29.36% (0.0991)
Change price per 3 year: -90.28% (0.72)
Change price per 5 year: -86% (0.5)
Change price per year to date: -12.5% (0.08)

Underestimation

Title Value Grade
P/S 5.24 3
P/BV 1.54 8
P/E 0 0
EV/EBITDA 0 0
Total: 3.88

Efficiency

Title Value Grade
ROA, % -18.37 0
ROE, % -25.95 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 37.39 5
Yield Ebitda, % 75.69 8
Yield EPS, % -35.71 0
Total: 2.6

Institutions Volume Share, %
DFA Asia Pacific Small Company Series 158304 0.04



Head Job title Payment Year of birth
Mr. Justin Cahill CFO & Company Secretary 85.56k
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director N/A 1969 (56 years)

Address: Australia, Abbotsford, 4-6 Southampton Crescent - open in Google maps, open in Yandex maps
Website: https://starpharma.com